Çiğdem Mermutluoğlu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Çiğdem Mermutluoğlu has a total of 200 co-authors. Here are the top co-authors by number of shared publications:
- Mustafa Kemal Çelen
Infectious Diseases and Clinical Microbiology, Dicle University, Diyarbakir, Turkey, Turkey (Türkiye)
7 shared publications - Ayşe Özlem Mete
Infectious Diseases and Clinical Microbiology, Gaziantep University, Gaziantep, Turkey, Turkey (Türkiye)
5 shared publications - Yakup Demir
Infectious Diseases Department, Memorial Hospital, Diyarbakır, Turkey (Türkiye), Turkey (Türkiye)
4 shared publications - Erdal Özbek
Department of Microbiology, Faculty of Medicine, Dicle University, Diyarbakır, Türkiye
3 shared publications Mustafa Kemal Çelen
3 shared publications- Safak Kaya
Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences, Gazi Yaşargil Training and Research Hospital, Diyarbakır 21070, Türkiye
3 shared publications
Latest Publications
- Open Access
Frequency of CAP-Defined Hepatic Steatosis and Its Association with Liver Fibrosis in Patients with Hepatitis Delta
Background and Aim: Hepatitis delta virus (HDV) infection is among the most aggressive forms of chronic viral hepatitis: fibrosis advances quickly, and cirrhosis, hepatocellular carcinoma (HCC) and hepatic decompensation develop more often than with other hepatitis viruses. Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading chronic liver disorder worldwide, and it may add to liver damage when it occurs alongside viral hepatitis. To date, however, data on hepatic steatosis in patients with chronic HDV infection remain scarce. We therefore aimed to describe the frequency of hepatic steatosis, assessed by the controlled attenuation parameter of transient elastography (FibroScan), in patients with chronic HBV infection and persistent anti-HDV seropositivity, and to examine whether it was associated with liver fibrosis. Methods: A total of 125 patients with chronic HBV infection and anti-HDV antibodies documented for at least six months were enrolled in this cross-sectional study between March and September 2024. HDV-RNA was tested in all participants. FibroScan provided liver stiffness measurement (LSM, kPa) and the controlled attenuation parameter (CAP, dB/m). We used CAP ≥ 248 dB/m to identify steatosis and LSM ≥ 12.5 kPa to identify cirrhosis. Because cardiometabolic risk factors were not systematically recorded, the criteria for MASLD could not be applied, and steatosis is reported as CAP-defined hepatic steatosis. Multivariable logistic regression was used to look for factors linked to LSM-defined advanced fibrosis (LSM ≥ 9.5 kPa), with sensitivity analyses accounting for ALT elevation. Results: The mean age was 39.0 years, and 74.4% (n = 93) of patients were male. HDV-RNA was detectable in 68.0% (n = 85). Of the 85 patients previously treated with pegylated interferon-alpha, 26 (30.6%) had a sustained virological response (SVR). Median LSM was 10.1 kPa (IQR 9.1–10.7) and median CAP 218 dB/m (IQR 211–239); cirrhosis was present in 15.2% (n = 19). CAP-defined steatosis was found in 24.0% (n = 30). Patients with and without steatosis were similar in age, sex, HDV-RNA status, liver stiffness, cirrhosis rate and SVR rate (36.4% vs. 28.6%, p = 0.593). After adjustment, detectable HDV-RNA was associated with advanced fibrosis (adjusted odds ratio [aOR] 4.89, 95% CI 2.13–11.26, p < 0.001), including after further adjustment for ALT. No significant association was found for steatosis (aOR 0.82, 95% CI 0.32–2.12, p = 0.684), although the confidence interval was wide. Conclusions: About one in four anti-HDV-positive patients had CAP-defined hepatic steatosis. Detectable HDV-RNA was associated with LSM-defined advanced fibrosis, whereas no significant association with steatosis was found; the precision of this estimate was limited, and the exploratory cirrhosis analysis was underpowered. Whether steatosis in this setting reflects metabolic dysfunction, and whether it affects long-term outcomes, warrants prospective study with full metabolic phenotyping.
Open AccessFrequency of CAP-Defined Hepatic Steatosis and Its Association with Liver Fibrosis in Patients with Hepatitis Delta
Background and Aim: Hepatitis delta virus (HDV) infection is among the most aggressive forms of chronic viral hepatitis: fibrosis advances quickly, and cirrhosis, hepatocellular carcinoma (HCC) and hepatic decompensation develop more often than with other hepatitis viruses. Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading chronic liver disorder worldwide, and it may add to liver damage when it occurs alongside viral hepatitis. To date, however, data on hepatic steatosis in patients with chronic HDV infection remain scarce. We therefore aimed to describe the frequency of hepatic steatosis, assessed by the controlled attenuation parameter of transient elastography (FibroScan), in patients with chronic HBV infection and persistent anti-HDV seropositivity, and to examine whether it was associated with liver fibrosis. Methods: A total of 125 patients with chronic HBV infection and anti-HDV antibodies documented for at least six months were enrolled in this cross-sectional study between March and September 2024. HDV-RNA was tested in all participants. FibroScan provided liver stiffness measurement (LSM, kPa) and the controlled attenuation parameter (CAP, dB/m). We used CAP ≥ 248 dB/m to identify steatosis and LSM ≥ 12.5 kPa to identify cirrhosis. Because cardiometabolic risk factors were not systematically recorded, the criteria for MASLD could not be applied, and steatosis is reported as CAP-defined hepatic steatosis. Multivariable logistic regression was used to look for factors linked to LSM-defined advanced fibrosis (LSM ≥ 9.5 kPa), with sensitivity analyses accounting for ALT elevation. Results: The mean age was 39.0 years, and 74.4% (n = 93) of patients were male. HDV-RNA was detectable in 68.0% (n = 85). Of the 85 patients previously treated with pegylated interferon-alpha, 26 (30.6%) had a sustained virological response (SVR). Median LSM was 10.1 kPa (IQR 9.1–10.7) and median CAP 218 dB/m (IQR 211–239); cirrhosis was present in 15.2% (n = 19). CAP-defined steatosis was found in 24.0% (n = 30). Patients with and without steatosis were similar in age, sex, HDV-RNA status, liver stiffness, cirrhosis rate and SVR rate (36.4% vs. 28.6%, p = 0.593). After adjustment, detectable HDV-RNA was associated with advanced fibrosis (adjusted odds ratio [aOR] 4.89, 95% CI 2.13–11.26, p < 0.001), including after further adjustment for ALT. No significant association was found for steatosis (aOR 0.82, 95% CI 0.32–2.12, p = 0.684), although the confidence interval was wide. Conclusions: About one in four anti-HDV-positive patients had CAP-defined hepatic steatosis. Detectable HDV-RNA was associated with LSM-defined advanced fibrosis, whereas no significant association with steatosis was found; the precision of this estimate was limited, and the exploratory cirrhosis analysis was underpowered. Whether steatosis in this setting reflects metabolic dysfunction, and whether it affects long-term outcomes, warrants prospective study with full metabolic phenotyping.
- Open Access
- 29 September 2026
- Published by MDPI AG in Preprints.org
Evaluation of the Frequency and Severity of MASLD in Patients with Chronic Hepatitis Delta
Background and Aim: Hepatitis delta virus (HDV) infection is among the most aggressive forms of chronic viral hepatitis: fibrosis advances quickly, and cirrhosis, hepatocellular carcinoma (HCC) and hepatic decompensation develop more often than with other hepatitis viruses. Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading chronic liver disorder worldwide, and it may add to liver damage when it occurs alongside viral hepatitis. To date, however, data on MASLD in patients with chronic HDV infection remain scarce. We therefore aimed to describe the frequency of MASLD, assessed by transient elastography (FibroScan), in patients with chronic HDV infection and to examine whether it was associated with the severity of liver fibrosis. Methods: A total of 125 anti-HDV seropositive patients were enrolled in this cross-sectional study between March and September 2024. HDV-RNA was tested in all participants. FibroScan provided liver stiffness measurement (LSM, kPa) and the controlled attenuation parameter (CAP, dB/m). We used CAP ≥248 dB/m to identify steatosis and LSM ≥12.5 kPa to identify cirrhosis. Because cardiometabolic risk factors were not systematically recorded, MASLD was defined operationally by CAP. Multivariable logistic regression was used to look for factors linked to advanced fibrosis (LSM ≥9.5 kPa). Results: The mean age was 39.0 years, and 74.4% (n=93) of patients were male. HDV-RNA was detectable in 68.0% (n=85). Of the 85 patients previously treated with pegylated interferon-alpha, 26 (30.6%) had a sustained virological response (SVR). The cohort had a mean LSM of 10.6 kPa and a mean CAP of 232.1 dB/m; cirrhosis was present in 15.2% (n=19). MASLD was found in 24.0% (n=30), and 20.0% (n=25) had steatosis together with LSM ≥7.0 kPa. Patients with and without MASLD were similar in age, sex, HDV-RNA status, liver stiffness, cirrhosis rate and SVR rate (36.4% vs. 28.6%, p=0.593). After adjustment, detectable HDV-RNA remained linked to advanced fibrosis (adjusted odds ratio [aOR] 4.89, 95% CI 2.13–11.26, p<0.001), whereas MASLD was not (aOR 0.82, 95% CI 0.32–2.12, p=0.684). Conclusion: About one in four patients with chronic HDV infection had hepatic steatosis, so viral and metabolic liver injury frequently coexist in this group. Fibrosis severity, however, was related to ongoing HDV replication rather than to steatosis. Whether this dual burden affects long-term outcomes warrants prospective evaluation.
- 29 September 2026
- Published by MDPI AG in Preprints.org
Open AccessEvaluation of the Frequency and Severity of MASLD in Patients with Chronic Hepatitis Delta
Background and Aim: Hepatitis delta virus (HDV) infection is among the most aggressive forms of chronic viral hepatitis: fibrosis advances quickly, and cirrhosis, hepatocellular carcinoma (HCC) and hepatic decompensation develop more often than with other hepatitis viruses. Metabolic dysfunction-associated steatotic liver disease (MASLD) is now the leading chronic liver disorder worldwide, and it may add to liver damage when it occurs alongside viral hepatitis. To date, however, data on MASLD in patients with chronic HDV infection remain scarce. We therefore aimed to describe the frequency of MASLD, assessed by transient elastography (FibroScan), in patients with chronic HDV infection and to examine whether it was associated with the severity of liver fibrosis. Methods: A total of 125 anti-HDV seropositive patients were enrolled in this cross-sectional study between March and September 2024. HDV-RNA was tested in all participants. FibroScan provided liver stiffness measurement (LSM, kPa) and the controlled attenuation parameter (CAP, dB/m). We used CAP ≥248 dB/m to identify steatosis and LSM ≥12.5 kPa to identify cirrhosis. Because cardiometabolic risk factors were not systematically recorded, MASLD was defined operationally by CAP. Multivariable logistic regression was used to look for factors linked to advanced fibrosis (LSM ≥9.5 kPa). Results: The mean age was 39.0 years, and 74.4% (n=93) of patients were male. HDV-RNA was detectable in 68.0% (n=85). Of the 85 patients previously treated with pegylated interferon-alpha, 26 (30.6%) had a sustained virological response (SVR). The cohort had a mean LSM of 10.6 kPa and a mean CAP of 232.1 dB/m; cirrhosis was present in 15.2% (n=19). MASLD was found in 24.0% (n=30), and 20.0% (n=25) had steatosis together with LSM ≥7.0 kPa. Patients with and without MASLD were similar in age, sex, HDV-RNA status, liver stiffness, cirrhosis rate and SVR rate (36.4% vs. 28.6%, p=0.593). After adjustment, detectable HDV-RNA remained linked to advanced fibrosis (adjusted odds ratio [aOR] 4.89, 95% CI 2.13–11.26, p<0.001), whereas MASLD was not (aOR 0.82, 95% CI 0.32–2.12, p=0.684). Conclusion: About one in four patients with chronic HDV infection had hepatic steatosis, so viral and metabolic liver injury frequently coexist in this group. Fibrosis severity, however, was related to ongoing HDV replication rather than to steatosis. Whether this dual burden affects long-term outcomes warrants prospective evaluation.
- Open Access
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8672
Baseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important comorbidity in people living with HIV (PLWH), yet most data derive from individuals receiving antiretroviral therapy (ART). In the baseline cross-sectional analysis of the prospective multicentre MASHIV-TR cohort (nine centres, Türkiye), we compared 250 newly diagnosed, ART-naïve PLWH and 161 HIV-negative controls. Hepatic steatosis and liver stiffness were assessed by vibration-controlled transient elastography; MASLD was defined as hepatic steatosis, indicated by CAP ≥ 248 dB/m together with at least one cardiometabolic risk factor. MASLD prevalence was similar in the two groups (25.2% vs. 30.4%; p = 0.245), and HIV status was not independently associated with MASLD. Triglyceride level was independently associated with CAP in PLWH (+10.69 dB/m per 50 mg/dL) and in controls (+9.26 dB/m), whereas CD4 and CD8 counts, the CD4/CD8 ratio and HIV-RNA were not associated with the liver outcomes. Before ART, hepatic steatosis tracked metabolic rather than HIV-specific markers.
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8672
Open AccessBaseline Liver Metabolic Health in Newly Diagnosed People Living with HIV Compared with HIV-Negative Controls: Cross-Sectional Findings from the Prospective MASHIV-TR Cohort
Metabolic dysfunction-associated steatotic liver disease (MASLD) is an important comorbidity in people living with HIV (PLWH), yet most data derive from individuals receiving antiretroviral therapy (ART). In the baseline cross-sectional analysis of the prospective multicentre MASHIV-TR cohort (nine centres, Türkiye), we compared 250 newly diagnosed, ART-naïve PLWH and 161 HIV-negative controls. Hepatic steatosis and liver stiffness were assessed by vibration-controlled transient elastography; MASLD was defined as hepatic steatosis, indicated by CAP ≥ 248 dB/m together with at least one cardiometabolic risk factor. MASLD prevalence was similar in the two groups (25.2% vs. 30.4%; p = 0.245), and HIV status was not independently associated with MASLD. Triglyceride level was independently associated with CAP in PLWH (+10.69 dB/m per 50 mg/dL) and in controls (+9.26 dB/m), whereas CD4 and CD8 counts, the CD4/CD8 ratio and HIV-RNA were not associated with the liver outcomes. Before ART, hepatic steatosis tracked metabolic rather than HIV-specific markers.
- 15 September 2026
- Published by Taylor & Francis in AIDS Care
- p. 1-12
AIDS-related and non-AIDS causes of in-hospital death among people living with HIV: a multicenter retrospective study
Human immunodeficiency virus (HIV) infection remains a major global public health challenge despite substantial advances in antiretroviral therapy (ART). According to the Joint United Nations Progr...
- 15 September 2026
- Published by Taylor & Francis in AIDS Care
- p. 1-12
AIDS-related and non-AIDS causes of in-hospital death among people living with HIV: a multicenter retrospective study
Human immunodeficiency virus (HIV) infection remains a major global public health challenge despite substantial advances in antiretroviral therapy (ART). According to the Joint United Nations Progr...
- Open Access
- 25 August 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1) , 1670
Multicentre insights into OPAT: a comprehensive analysis of Türkiye’s unstructured system
Outpatient parenteral antimicrobial therapy (OPAT) is a well-established, cost-effective treatment modality delivered through structured, multidisciplinary
- 25 August 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1) , 1670
Open AccessMulticentre insights into OPAT: a comprehensive analysis of Türkiye’s unstructured system
Outpatient parenteral antimicrobial therapy (OPAT) is a well-established, cost-effective treatment modality delivered through structured, multidisciplinary
- Open Access
Admission Electrolyte Abnormalities and Clinical Outcomes in Hospitalized COVID-19 Patients
Background and Objectives: Electrolyte abnormalities are frequently observed in hospitalized patients with acute infections and may reflect underlying disease severity. This study aimed to investigate the association between baseline electrolyte disturbances and clinical outcomes in patients with COVID-19, with a particular focus on albumin-corrected calcium levels. Materials and Methods: This retrospective study included 348 hospitalized patients with COVID-19. Primary analyses were restricted to RT-PCR-confirmed cases (n = 272) to minimize misclassification bias, while the full cohort was evaluated in sensitivity analyses. Baseline electrolyte levels at admission were recorded, and corrected calcium levels were calculated using serum albumin. Clinical outcomes included prolonged hospitalization (defined relative to the cohort median), intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and in-hospital mortality. Multivariable logistic regression analyses were performed adjusting for age, sex, and renal function (eGFR). Results: In the PCR-confirmed cohort, corrected hypocalcemia was present in 37.3% of patients. In univariate analyses, hypocalcemia, hyponatremia, and hypophosphatemia were significantly associated with adverse outcomes. However, after adjustment, corrected hypocalcemia did not retain independent significance. Hyponatremia remained independently associated with ICU admission (OR: 9.45, 95% CI: 2.12–42.1, p = 0.003), while hypophosphatemia was independently associated with prolonged hospitalization (OR: 2.83, 95% CI: 1.36–5.91, p = 0.005). No electrolyte abnormality demonstrated a stable independent association with IMV requirement or mortality after adjustment. Sensitivity analyses in the full cohort yielded consistent findings. Conclusions: Electrolyte abnormalities are common in hospitalized COVID-19 patients and are associated with worse clinical outcomes; however, they primarily reflect overall disease severity rather than acting as independent prognostic determinants. Routine electrolyte measurements may provide accessible and clinically informative markers but should be interpreted in conjunction with other clinical parameters.
Open AccessAdmission Electrolyte Abnormalities and Clinical Outcomes in Hospitalized COVID-19 Patients
Background and Objectives: Electrolyte abnormalities are frequently observed in hospitalized patients with acute infections and may reflect underlying disease severity. This study aimed to investigate the association between baseline electrolyte disturbances and clinical outcomes in patients with COVID-19, with a particular focus on albumin-corrected calcium levels. Materials and Methods: This retrospective study included 348 hospitalized patients with COVID-19. Primary analyses were restricted to RT-PCR-confirmed cases (n = 272) to minimize misclassification bias, while the full cohort was evaluated in sensitivity analyses. Baseline electrolyte levels at admission were recorded, and corrected calcium levels were calculated using serum albumin. Clinical outcomes included prolonged hospitalization (defined relative to the cohort median), intensive care unit (ICU) admission, invasive mechanical ventilation (IMV), and in-hospital mortality. Multivariable logistic regression analyses were performed adjusting for age, sex, and renal function (eGFR). Results: In the PCR-confirmed cohort, corrected hypocalcemia was present in 37.3% of patients. In univariate analyses, hypocalcemia, hyponatremia, and hypophosphatemia were significantly associated with adverse outcomes. However, after adjustment, corrected hypocalcemia did not retain independent significance. Hyponatremia remained independently associated with ICU admission (OR: 9.45, 95% CI: 2.12–42.1, p = 0.003), while hypophosphatemia was independently associated with prolonged hospitalization (OR: 2.83, 95% CI: 1.36–5.91, p = 0.005). No electrolyte abnormality demonstrated a stable independent association with IMV requirement or mortality after adjustment. Sensitivity analyses in the full cohort yielded consistent findings. Conclusions: Electrolyte abnormalities are common in hospitalized COVID-19 patients and are associated with worse clinical outcomes; however, they primarily reflect overall disease severity rather than acting as independent prognostic determinants. Routine electrolyte measurements may provide accessible and clinically informative markers but should be interpreted in conjunction with other clinical parameters.
- Open Access
- 23 December 2025
- Published by Galenos Yayinevi in Viral Hepatitis Journal
Find HDV and Determine Its Status in Türkiye “SITU(HD)VATION TÜRKİYE”
Find HDV and Determine Its Status in Türkiye “SITU(HD)VATION TÜRKİYE” - Viral Hepatitis Journal
- 23 December 2025
- Published by Galenos Yayinevi in Viral Hepatitis Journal
Open AccessFind HDV and Determine Its Status in Türkiye “SITU(HD)VATION TÜRKİYE”
Find HDV and Determine Its Status in Türkiye “SITU(HD)VATION TÜRKİYE” - Viral Hepatitis Journal
- Open Access
- 16 December 2025
- Published by Science Publishing Group in International Journal of Infectious Diseases and Therapy
- Vol. 10 (4) , 68-84
Current Clinical Applications of Entecavir in Hepatitis B Viruses Infection
Entecavir (ETV) is a guanosine nucleoside analogue widely used in the management of chronic Hepatitis B Virus (HBV) infection. It demonstrates consistent antiviral activity, favourable tolerability, and a high genetic barrier to resistance, making it a reliable option across diverse clinical settings. Evidence from clinical trials and real-world studies confirms that ETV achieves sustained viral suppression, alanine aminotransferase (ALT) normalization, and histological improvement, contributing to reduced long-term risks of cirrhosis and hepatocellular carcinoma. Its pharmacokinetic properties and antiviral effectiveness have been established in both treatment-naïve and lamivudine-resistant patients. ETV maintains clinical utility in various special populations, including individuals with decompensated cirrhosis, chronic kidney disease, post-transplant status, and those receiving immunosuppressive therapy. In these groups, ETV retains efficacy with limited drug-drug interactions and a generally mild adverse-event profile. Optimal adherence to therapy remains essential to ensure sustained viral suppression and minimize the risk of treatment failure. In addition to established clinical roles, emerging research has explored new formulations and potential therapeutic applications of ETV, including long-acting delivery strategies and its possible relevance in oncologic contexts. These developments highlight continued interest in optimizing the use of ETV in HBV management. Overall, ETV remains a well-supported antiviral agent that combines durable efficacy, safety, and broad applicability in the treatment of chronic HBV infection.
- 16 December 2025
- Published by Science Publishing Group in International Journal of Infectious Diseases and Therapy
- Vol. 10 (4) , 68-84
Open AccessCurrent Clinical Applications of Entecavir in Hepatitis B Viruses Infection
Entecavir (ETV) is a guanosine nucleoside analogue widely used in the management of chronic Hepatitis B Virus (HBV) infection. It demonstrates consistent antiviral activity, favourable tolerability, and a high genetic barrier to resistance, making it a reliable option across diverse clinical settings. Evidence from clinical trials and real-world studies confirms that ETV achieves sustained viral suppression, alanine aminotransferase (ALT) normalization, and histological improvement, contributing to reduced long-term risks of cirrhosis and hepatocellular carcinoma. Its pharmacokinetic properties and antiviral effectiveness have been established in both treatment-naïve and lamivudine-resistant patients. ETV maintains clinical utility in various special populations, including individuals with decompensated cirrhosis, chronic kidney disease, post-transplant status, and those receiving immunosuppressive therapy. In these groups, ETV retains efficacy with limited drug-drug interactions and a generally mild adverse-event profile. Optimal adherence to therapy remains essential to ensure sustained viral suppression and minimize the risk of treatment failure. In addition to established clinical roles, emerging research has explored new formulations and potential therapeutic applications of ETV, including long-acting delivery strategies and its possible relevance in oncologic contexts. These developments highlight continued interest in optimizing the use of ETV in HBV management. Overall, ETV remains a well-supported antiviral agent that combines durable efficacy, safety, and broad applicability in the treatment of chronic HBV infection.
- Open Access
- 30 July 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (3) , 169-176
An investigation of the role of trace elements and biochemical parameters in patients with COVID-19
Aim: The COVID-19 pandemic is an emergent viral respiratory disease characterized by high fever and shortness of breath, and it was declared a pandemic by the World Health Organization in March 2020. Early assessment of patients’ biochemical tests is important for accelerating diagnosis, allowing effective treatment, and controlling the further spread of the disease. The present study aimed to investigate the association between the disease, trace elements -including copper (Cu), zinc (Zn), selenium (Se), manganese (Mn), and cobalt (Co) vitamin D, Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) biochemical levels, and the correlation between the parameters tested in patients with COVID-19. Methods: In our study, 40 patients (case group) who were hospitalized with a diagnosis of COVID-19 based on chest X-ray images and RT-PCR results evaluated by an infectious diseases specialist were included, along with 40 healthy individuals (control group) over the age of 18 who had no prior symptoms of COVID-19, no visits to a medical doctor for COVID-19, and no history of hospitalization due to the disease. Beckman Coulter AU5800 (Beckman Coulter, Brea, CA, USA) autoanalyzer was used for spectrophotometric analyses of clinical biochemistry tests, and vitamin D levels were examined using the HPLC method with the Shimadzu SIL-20A HT autosampler. Levels of trace elements-including Cu, Zn, Se, Mn, and Co-were measured by inductively coupled plasma mass spectrometry (ICP-MS) on an ICP-MS Bruker Aurora M90 analytical complex. The normal distribution hypothesis for the variables in question was tested using the Kolmogorov–Smirnov test. Student’s t-test was used for intergroup comparisons of variables meeting the normal distribution hypothesis, whereas Mann–Whitney U test was used for variables that did not meet the hypothesis. Results: Vitamin D levels were much lower in the case group (12.05 ng/mL ± 6.27) compared to the control group (23.54 ng/mL ± 10.54), and the difference was statistically significant (p < 0.001). Serum Cu, Zn, Se, Mn, and Co levels in the control group were higher compared to the COVID-19 group, yet only the differences in Zn, Se, and Mn levels were statistically significant (p
- 30 July 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (3) , 169-176
Open AccessAn investigation of the role of trace elements and biochemical parameters in patients with COVID-19
Aim: The COVID-19 pandemic is an emergent viral respiratory disease characterized by high fever and shortness of breath, and it was declared a pandemic by the World Health Organization in March 2020. Early assessment of patients’ biochemical tests is important for accelerating diagnosis, allowing effective treatment, and controlling the further spread of the disease. The present study aimed to investigate the association between the disease, trace elements -including copper (Cu), zinc (Zn), selenium (Se), manganese (Mn), and cobalt (Co) vitamin D, Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) biochemical levels, and the correlation between the parameters tested in patients with COVID-19. Methods: In our study, 40 patients (case group) who were hospitalized with a diagnosis of COVID-19 based on chest X-ray images and RT-PCR results evaluated by an infectious diseases specialist were included, along with 40 healthy individuals (control group) over the age of 18 who had no prior symptoms of COVID-19, no visits to a medical doctor for COVID-19, and no history of hospitalization due to the disease. Beckman Coulter AU5800 (Beckman Coulter, Brea, CA, USA) autoanalyzer was used for spectrophotometric analyses of clinical biochemistry tests, and vitamin D levels were examined using the HPLC method with the Shimadzu SIL-20A HT autosampler. Levels of trace elements-including Cu, Zn, Se, Mn, and Co-were measured by inductively coupled plasma mass spectrometry (ICP-MS) on an ICP-MS Bruker Aurora M90 analytical complex. The normal distribution hypothesis for the variables in question was tested using the Kolmogorov–Smirnov test. Student’s t-test was used for intergroup comparisons of variables meeting the normal distribution hypothesis, whereas Mann–Whitney U test was used for variables that did not meet the hypothesis. Results: Vitamin D levels were much lower in the case group (12.05 ng/mL ± 6.27) compared to the control group (23.54 ng/mL ± 10.54), and the difference was statistically significant (p < 0.001). Serum Cu, Zn, Se, Mn, and Co levels in the control group were higher compared to the COVID-19 group, yet only the differences in Zn, Se, and Mn levels were statistically significant (p
- Open Access
- 30 July 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (3) , 169-176
An investigation of the role of trace elements and biochemical parameters in patients with COVID-19
Aim: The COVID-19 pandemic is an emergent viral respiratory disease characterized by high fever and shortness of breath, and it was declared a pandemic by the World Health Organization in March 2020. Early assessment of patients’ biochemical tests is important for accelerating diagnosis, allowing effective treatment, and controlling the further spread of the disease. The present study aimed to investigate the association between the disease, trace elements -including copper (Cu), zinc (Zn), selenium (Se), manganese (Mn), and cobalt (Co) vitamin D, Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) biochemical levels, and the correlation between the parameters tested in patients with COVID-19. Methods: In our study, 40 patients (case group) who were hospitalized with a diagnosis of COVID-19 based on chest X-ray images and RT-PCR results evaluated by an infectious diseases specialist were included, along with 40 healthy individuals (control group) over the age of 18 who had no prior symptoms of COVID-19, no visits to a medical doctor for COVID-19, and no history of hospitalization due to the disease. Beckman Coulter AU5800 (Beckman Coulter, Brea, CA, USA) autoanalyzer was used for spectrophotometric analyses of clinical biochemistry tests, and vitamin D levels were examined using the HPLC method with the Shimadzu SIL-20A HT autosampler. Levels of trace elements-including Cu, Zn, Se, Mn, and Co-were measured by inductively coupled plasma mass spectrometry (ICP-MS) on an ICP-MS Bruker Aurora M90 analytical complex. The normal distribution hypothesis for the variables in question was tested using the Kolmogorov–Smirnov test. Student’s t-test was used for intergroup comparisons of variables meeting the normal distribution hypothesis, whereas Mann–Whitney U test was used for variables that did not meet the hypothesis. Results: Vitamin D levels were much lower in the case group (12.05 ng/mL ± 6.27) compared to the control group (23.54 ng/mL ± 10.54), and the difference was statistically significant (p < 0.001). Serum Cu, Zn, Se, Mn, and Co levels in the control group were higher compared to the COVID-19 group, yet only the differences in Zn, Se, and Mn levels were statistically significant (p
- 30 July 2025
- Published by Izzet Baysal Training and Research Hospital in Northwestern Medical Journal
- Vol. 5 (3) , 169-176
Open AccessAn investigation of the role of trace elements and biochemical parameters in patients with COVID-19
Aim: The COVID-19 pandemic is an emergent viral respiratory disease characterized by high fever and shortness of breath, and it was declared a pandemic by the World Health Organization in March 2020. Early assessment of patients’ biochemical tests is important for accelerating diagnosis, allowing effective treatment, and controlling the further spread of the disease. The present study aimed to investigate the association between the disease, trace elements -including copper (Cu), zinc (Zn), selenium (Se), manganese (Mn), and cobalt (Co) vitamin D, Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) biochemical levels, and the correlation between the parameters tested in patients with COVID-19. Methods: In our study, 40 patients (case group) who were hospitalized with a diagnosis of COVID-19 based on chest X-ray images and RT-PCR results evaluated by an infectious diseases specialist were included, along with 40 healthy individuals (control group) over the age of 18 who had no prior symptoms of COVID-19, no visits to a medical doctor for COVID-19, and no history of hospitalization due to the disease. Beckman Coulter AU5800 (Beckman Coulter, Brea, CA, USA) autoanalyzer was used for spectrophotometric analyses of clinical biochemistry tests, and vitamin D levels were examined using the HPLC method with the Shimadzu SIL-20A HT autosampler. Levels of trace elements-including Cu, Zn, Se, Mn, and Co-were measured by inductively coupled plasma mass spectrometry (ICP-MS) on an ICP-MS Bruker Aurora M90 analytical complex. The normal distribution hypothesis for the variables in question was tested using the Kolmogorov–Smirnov test. Student’s t-test was used for intergroup comparisons of variables meeting the normal distribution hypothesis, whereas Mann–Whitney U test was used for variables that did not meet the hypothesis. Results: Vitamin D levels were much lower in the case group (12.05 ng/mL ± 6.27) compared to the control group (23.54 ng/mL ± 10.54), and the difference was statistically significant (p < 0.001). Serum Cu, Zn, Se, Mn, and Co levels in the control group were higher compared to the COVID-19 group, yet only the differences in Zn, Se, and Mn levels were statistically significant (p